AstraZeneca’s (AZN) Top Pick Rating Reaffirmed at Barclays

Share on StockTwits

Barclays reissued their top pick rating on shares of AstraZeneca (LON:AZN) in a report released on Friday morning, Marketbeat.com reports. Barclays currently has a GBX 6,800 ($88.85) price objective on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on AZN. Credit Suisse Group set a GBX 5,900 ($77.09) target price on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 27th. Kepler Capital Markets set a GBX 5,630 ($73.57) target price on shares of AstraZeneca and gave the company a buy rating in a research report on Wednesday, August 1st. Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Thursday. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Tuesday, October 30th. Finally, UBS Group set a GBX 5,900 ($77.09) target price on shares of AstraZeneca and gave the company a neutral rating in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca has a consensus rating of Hold and a consensus target price of GBX 5,831.89 ($76.20).

Shares of AZN traded up GBX 79 ($1.03) during midday trading on Friday, reaching GBX 6,172 ($80.65). The stock had a trading volume of 2,861,442 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: How much money do you need to begin day trading?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.